TGIA
SPRO icon

Torrey Growth & Income Advisors’s Spero Therapeutics SPRO Stock Holding History

Torrey Growth & Income Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,025
Closed -$37.6K – 120
2026
Q1 		$37.6K Hold
17,025
– – 0.02% 109
2025
Q4 		$39.7K Buy
17,025
+1,250
+8% +$2.9K 0.01% 109
2025
Q3 		$29.7K Buy
+15,775
New +$34.7K 0.01% 125

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Torrey Growth & Income Advisors's SPRO Position: Q2 2026 in Review

Torrey Growth & Income Advisors sold out of Spero Therapeutics (SPRO) in Q2 2026, closing a stake of 17,025 shares — an estimated $37.6K sold.

Torrey Growth & Income Advisors first reported a position in SPRO in Q3 2025 and held it in 3 quarters. The position peaked at $39.7K in Q4 2025. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Torrey Growth & Income Advisors reported no remaining Spero Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Torrey Growth & Income Advisors sold 17,025 Spero Therapeutics shares in Q2 2026, an estimated $37.6K.
  • Torrey Growth & Income Advisors first reported a position in Spero Therapeutics in Q3 2025 and held it in 3 quarters.
  • Torrey Growth & Income Advisors's Spero Therapeutics position peaked at $39.7K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Torrey Growth & Income Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.